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Available online 8 September 2014Abstract An emerging therapeutic approach for Duchenne muscular dystrophy is the transplantation of autologous myogenic
progenitor cells genetically modified to express dystrophin. The use of this approach is challenged by the difficulty in maintaining
these cells ex vivo while keeping their myogenic potential, and ensuring sufficient transgene expression following their
transplantation and myogenic differentiation in vivo. We investigated the use of the piggyBac transposon system to achieve stable
gene expression when transferred to cultured mesoangioblasts and into murine muscles. Without selection, up to 8% of the
mesoangioblasts expressed the transgene from 1 to 2 genomic copies of the piggyBac vector. Integration occurred mostly in
intergenic genomic DNA and transgene expression was stable in vitro. Intramuscular transplantation of mouse Tibialis anterior
muscles with mesoangioblasts containing the transposon led to sustained myofiber GFP expression in vivo. In contrast, the direct
electroporation of the transposon-donor plasmids in the mouse Tibialis muscles in vivo did not lead to sustained transgene
expression despite molecular evidence of piggyBac transposition in vivo. Together these findings provide a proof-of-principle that
piggyBac transposon may be considered for mesoangioblast cell-based therapies of muscular dystrophies.
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Duchenne muscular dystrophy (DMD) is characterized by a
progressive muscle degeneration caused by mutations in one
of the largest gene known, that of dystrophin (Koenig et al.,
1987). There is no curative treatment at present and death
usually occurs within 10 to 15 years of symptom onset,
typically from breathing complications and cardiomyopathy
(Emery, 1993). Current promising clinical and pre-clinical
approaches include gene editing, exon skipping, gene
therapy and stem cell therapies (Fairclough et al., 2013).
Of these, exon skipping is currently most advanced, where
the delivery or expression of small RNAs affecting splicing is
used to remove a mutated dystrophin mRNA exon. However,open access article under the CC BY license
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type of the dystrophin gene mutation (Brolin and Shiraishi,
2011).
Other gene therapy strategies aim at the delivery of a
functional dystrophin coding sequence into the dystrophic
muscle of DMD patients. Viral vectors are commonly used in
gene therapy for their efficient gene delivery and integra-
tion in the myofiber genomes, but their use may be limited
to the expression of truncated dystrophin variants, due to
cargo-size limitations of the viral capsid (Phelps et al., 1995;
Duan et al., 1998). In addition, safety concerns were linked
to malignant cell transformation due to insertional muta-
genesis linked to certain viral vectors (Hacein-Bey-Abina
et al., 2008; Lewinski and Bushman, 2005), whereas the
immunogenicity of the viral particles is also a concern (Raper
et al., 2003; Yei et al., 1994). Thus, alternatives to viral
vector gene transfer are also currently assessed. For
instance, an alternative gene transfer method is the in vivo
electroporation of naked plasmids containing the dystrophin
gene, which has little transgene size constraint and low
immunogenicity. Plasmids or synthetic chromosomes can
persist in the muscle fiber without genome integration
and transgene expression can be relatively stable in the
non-dividing myofibers (Puttini et al., 2009; Tedesco et al.,
2011). However, the long-term expression of the transgene
may be reduced by gradual silencing effects and/or by the
loss of the episomal DNA.
Thus, the persistent muscle expression of full length
dystrophin remains difficult to achieve currently. Since the
discovery of satellite stem cells and the difficulties met in
maintaining their differentiation potential during in vitro
culture, several promising alternative candidates for DMD
cell therapy have been identified. These include the blood
vessel-associated mesoangioblast muscle precursor cells,
as they are expandable in vitro and capable of systemic
myogenic differentiation following intra-arterial injection
(Cossu and Bianco, 2003). It was shown that mesoangioblasts
from wild-type donors could restore functional and systemic
dystrophin expression after intra-arterial transplantation in
the golden retriever muscular dystrophy dog model, which
led to increased life-span and improved muscle function and
mobility (Sampaolesi et al., 2006). However, the outcome of
the transfer of viral vector-transduced autologous cells
expressing a truncated dystrophin was less encouraging.
One current challenge for the in vitro engineering of
these cells using non-viral vectors is that they are difficult to
transfect and have a limited expansion potential. Ideally,
the complete dystrophin sequence should be stably inte-
grated in low-copy number in non-coding sequences of
the mesoangioblast genome, avoiding the mis-regulation of
endogenous genes while allowing sufficient transgene
expression to maintain efficacy. Transfer of the full-length
dystrophin cDNA may be achieved via non-viral transfection
methods that include chemical reagents and electropora-
tion. However, the low transfection and integration rates
and/or frequent transgene silencing of the non-viral vectors
have limited progress for their use in mesoangioblasts
(Tedesco et al., 2011; Murakami et al., 2003; Van Zwieten
et al., submitted for publication; Yanagihara et al., 1996).
The enrichment of a subpopulation of cells that display
stable expression following transgene integration may thus
be required, which is difficult to achieve using clinicallyacceptable practice, for instance because in vitro cell
expansion can increase the likelihood of chromosomal
rearrangement occurrence.
As a potential response to these issues, the piggyBac (PB)
and Sleeping Beauty transposon systems may be proposed as
alternatives, as they combine the relatively easier produc-
tion of non-viral vectors with the efficient transgene
integration and sustained expression in a broad variety of
cell types (Ding et al., 2005; Handler et al., 1998; Ivics et al.,
1997, 2009; Wilson et al., 2007). Among the known DNA
transposons and integrating viral vectors, PB has the unique
property to integrate cargos of up to 20 kb in mammalian
cells without a significant loss of transposition efficiency
(Ding et al., 2005). Moreover, PB has demonstrated its
potential for gene or cell therapy applications, in particular
in the context of difficult-to-transfect human embryonic
stem cells or T-lymphocytes, and for the generation of
induced pluripotent stem cells (Ding et al., 2005). Further-
more, incorporation of a epigenetic regulatory element,
hMAR (human matrix attachment region) 1–68, in a PB
transposon cassette, was shown to decrease silencing effect
and to stabilize and increase transgene expression in
cultured cell lines (Ley et al., 2013). However, the efficacy
of PB transposon vectors has not been investigated in
mesoangioblasts or in muscles in vivo.
Here, we addressed whether the use of PB vectors
may allow stable transgene delivery and expression in
mesoangioblasts following their transplantation into mouse
muscles, and we assessed their performance relative to
in vivo electroporation-mediated DNA delivery to mouse
muscle. The PB vector was found to yield stable GFP
expression in mesoangioblasts in culture as well as after
their in vivo differentiation and fusion to myofibers
following transplantation. The widespread expression
observed from mesoangioblast transplantation was found to
be persistent, unlike that obtained from the direct in situ
muscle electroporation with the transposable vector DNA,
despite the documented transposition events that occurred
in vivo with this later approach. These findings indicated
that PB vectors may provide a viable approach to achieve
efficient and stable gene transfer in the context of DMD
therapy.Materials and methods
Plasmids and DNA vectors
The PB transposase expression vector pCS2+U5V5PBU3
containing the PB transposase coding sequence surrounded
by the 5′ and 3′ untranslated terminal regions (UTR) of the
Xenopus laevis β-globin gene (Fig. 1, left panel) was
constructed as previously described (Ley et al., 2013). The
different transposon vectors used in this study were
generated by introducing the PB 235 bp 3′ and 310 bp 5′
inverted terminal repeats (ITRs) into the pBluescript
SK-plasmid (Fig. 1, right panel). The MAR 1–68 element,
the puromycin resistance and green fluorescent protein
(GFP) genes used in this study were as previously described
(Girod et al., 2007; Hart and Laemmli, 1998; Grandjean
et al., 2011). The puromycin resistance gene (Puro) was under
the control of the SV40 promoter originated from pRc/RSV
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expressed using a eukaryotic expression cassette composed of
a human cytomegalovirus (CMV) enhancer and human glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) promoter
upstream of the coding sequence followed by a simian virus
40 (SV40) polyadenylation signal, the human gastrin termina-
tor and a SV40 enhancer (Le Fourn et al., 2013). A DNA spacer
of 3.6 kb corresponding to the MAR 1–68 length was
polymerase chain reaction (PCR)-amplified from the mouse
utrophin cDNA and used as control without MAR. The human
GAPDH promoter was replaced by the SV40 promoter using
standard cloning methods to assess GFP expression from a
weak promoter in the context of transposable vectors (Fig.
S3). Expression cassettes and/or MAR elements were inserted
between the ITR sequences as illustrated in Fig. 1 using
standard cloning methods.Cell culture and transfections
The dystrophic (mdx) mesoangioblasts were kindly provided
by G. Cossu and collaborators and cultivated in Dulbecco's
modified eagle medium (DMEM, Gibco) containing 20% fetal
bovine serum (FBS, Gibco) as previously described (Tonlorenzi
et al., 2007). C2C12 mouse myoblasts were maintained in
DMEM (Gibco) containing 10% FBS. For differentiation assay,
mesoangioblasts and a 4-fold excess of C2C12 cells were
co-cultured in DMEM for 24 h, after which cells were placed in
differentiation medium, consisting of DMEM supplemented
with 2% horse serum, for 5 days. Myofibers were fixed in 3%
paraformaldehyde and immunostained with the primary
mouse antibody anti-α-actinin (1:500, clone EA-53; Sigma)
and secondary antibody Alexa Fluor 546-conjugated
anti-mouse IgG (1:2000, Molecular Probes). Cell nuclei were
counterstained with DAPI.
Transfectionswere performed using polyethylenimine (PEI)
(JetPRIME, Polyplus Transfection) or Neon electroporation
(Invitrogen) according to the manufacturer's instructions.Figure 1 Overview of the PB expression constructs used in this st
coding sequence (PB), the bacterial origin of replication (Ori) and th
the plasmids used in this study. The puromycin resistance (Puro) and
yellow and green arrows, and the spacer utrophin coding sequenc
respectively, on the transposon donor plasmid derivatives.For titration experiments using PEI, 150,000 cells were
co-transfected with various amounts of circular PB transposase
plasmid (ranging from 0 to 2.5 μg) and a fixed amount of
1.5 μg of circular transposon plasmid. For transposition
experiments using PEI, 150,000 cells were co-transfected
with 1 μg of circular PB transposase plasmid and 1.5 μg of
circular transposon plasmids (optimal ratio of 1:1.5). For
electroporations, 500,000 cells were co-transfected with 3 μg
of circular transposase PB plasmid and 4.5 μg of circular
transposon plasmid by two 1300 V pulses of 20 ms. For
transposition experiments without selection, cells were passed
every 2 days for 3 weeks in normal medium. For transposition
experiment with selection, cells were placed in media
containing 2 μg/ml puromycin 48 h after transfection and
theywere further cultured for 3 weeks. Cells were analyzed for
GFP fluorescence by fluorescence-activated cell sorting (FACS)
on day 2 after transfection to assess transient transfection
efficiency analysis, and after 21 days of culture for transposi-
tion efficiency analysis. To determine the transgene copy
number of unselected cells, stable GFP-expressing cells were
sorted using a FACSAriaII. For GFP expression stability analysis,
the percentage and fluorescence levels of GFP-positive sorted
cells were followed by FACS for 1 month.qPCR gene copy number assays
Genomic DNA was extracted and purified from unselected
and selected stable GFP-expressing mesoangioblasts and
Tibialis mouse muscles using the DNeasy Tissue Kit (Qiagen,
Hilden, Germany) according to the manufacturer's protocol.
Quantitative real-time PCR (qRT-PCR) relied on the SYBR
Green-Taq polymerase kit from Eurogentec Inc. and ABI
Prism 7700 PCR machine (Applied Biosystems), as adapted to
estimate the number of genome-integrated transgene copies
from 50 ng of genomic DNA. The GFP-Forward ACATTATG
CCGGACAAAGCC and GFP-Reverse TTGTTTGGTAATGA TCA
GCAAGTTG primers were used to amplify the GFP gene. Theudy. The PB inverted terminal repeats (ITR), the PB transposase
e ampicillin selection gene (Amp) are schematically depicted on
reporter green fluorescent protein (GFP) genes are illustrated by
e and MAR 1–68 element are shown by white and red boxes,
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CAGGAAACAGCTATGACCATG primers were used to amplify
excised plasmids for the transposon excision quantifica-
tion assay. The Ftsj2-Forward GGGACCATCCATACCTTCG and
Ftsj2-Reverse: GCTTGCTGGTGGTTTCCTC primers were used
to amplify the Ftsj2 endogenous gene. The amplicon gener-
ated by the Ftsj2 primers gives one hit per haploid mouse
genome using NCBI BLAST software. As mouse genome is
diploid, we estimated that Ftsj2 is present at 2 copies per
genome. The relative number of transgene copies per cell
corresponded to the ratio between transgene and endogenous
gene copies (Karlen et al., 2007).
Genomic integration site analysis and mapping
To determine the genomic integration sites of transfected
mesoangioblasts and electroporated Tibialis mouse muscles,
obtained as described in the “qPCR gene copy number
assays” section above, we used the APAgeneTM GOLD
Genome Walking kit to isolate unknown DNA sequences
flanking known sequences, according to manufacturer's
instruction. 3 specific primers were designed to anneal the
end of the known 3′ ITR sequence for the nested PCR
amplification steps, namely ACCGCATTGACAAGCACGCCTC
AC, AGCGGCGACTGAGATGTCCTAAATG and CGACGGATTCGC
GCTATTTAGAAAG in sequential order. The final PCR prod-
ucts were extracted from agarose gel and sequenced.
Mapping of PB integration sites was performed using the UC
Santa Cruz BLAT genome web-browser (mouse, December
2011 assembly). Only the sequencing results revealing an
intact donor plasmid composed of the end of the 3′ ITR and a
TTAA tetranucleotide marking the PB transposon border
followed by a genomic sequence of at least 50 bp were taken
into account. True PB integration sites were considered
if the genomic sequence started immediately after the
terminal TTAA at the end of the 3′ ITR sequence and
matched at genomic locus with 95% identity. Distances of
integration sites relative to gene on 5′ and 3′ side of the
integration sites correspond to the distances between the
stop codon of the downstream gene and between the ATG of
the upstream gene and the integration site respectively
(Figs. 4C and D).
Intramuscular mesoangioblast transplantation in
nude mice
All animal experiments were done in accordance with
institutional guidelines and authorizations for animal re-
search by the State of Vaud veterinary office. In vivo
experiments were done in 7-week-old CD1 nude mice
(Charles River, USA). The wild-type mesoangioblasts were
provided by G. Cossu and collaborators and cultivated as
described in “Cell culture and transfection analysis” part.
The Puro-GFP transposon and transposase plasmids were
transfected in 1,000,000 mesoangioblasts per condition
by NEON electroporation (Invitrogen) using the settings:
1300 V, 20 ms, and 2 pulses. Cells were co-transfected with
3 μg of transposase and 12 μg of transposon plasmids (ratio
of 1:4) and a respective control in which the transposase
plasmid was replaced by PB-devoid plasmid. All the cells
were harvested 24 h after electroporation and 500,000 cellswere resuspended in 25 μl PBS and transplanted into
the Tibialis anterior muscle by intramuscular injection
(3 muscles per time point, 1 injection trajectory per muscle).
Tibialis anterior muscles were pre-injected with 25 μl
cardiotoxin (10 μM) 24 h prior to transplantation of cells. 10,
30 and 60 days after transplantation,micewere sacrificed and
the Tibialis anterior muscles were isolated.Intramuscular electrotransfer of PB transposon
in mice
In vivo electrotransfer was carried out on 5 week-old C57BL6
female mice (Iffa Credo-Charles River, France). Animals
were housed in a facility with food and water ad libitum. The
Tibialis anterior muscles were pre-treated with 0.8 U/μl of
bovine hyaluronidase in 25 μl of normal saline 2–4 h before
plasmid injection using a Hamilton syringe. Plasmid DNA in
normal saline prepared by CsCl purification was injected
intramuscularly. Four conditions were tested: 6 μg of the PB
plasmid or control plasmid without transposase mixed with
20 μg of Puro-GFP or Puro-GFP-MAR transposon plasmids.
All injections (30 μl) were carried out inside the Tibialis
anterior muscle of four mice per condition, under Ketaminol
(100 mg/kg) and Narcoxyl (75 mg/kg). Following the intra-
muscular injection of DNA, an electrical field of 200 V/cm in
8 ms pulses at 1 Hz (BTX electroporator) was applied to the
muscle. Muscles were dissected after 7 days, 1 month and
9 months following electrotransfer.Histochemical and quantification analysis of
mouse muscles
Directly after dissection, GFP fluorescence in the whole
Tibialis anterior muscle was observed by fluorescence
microscopy. Then, muscles were embedded in gum traga-
canth, frozen in isopentane at liquid nitrogen temperature,
and stored at −80 °C for further analysis. 10 μm serial
sections of the Tibialis muscles were prepared using a
Cryostat at −25 °C. Sections were mounted onto glass slides
and directly observed by fluorescence microscopy for
GFP-positive myofiber analysis. To visualize the myofiber
membranes, the sections were fixed in 3% paraformaldehyde
and stained with Alexa594-conjugated agglutinin. For the
assessment of tissue damage and morphology, sections were
stained with hematoxylin–eosin, as described in Berry et al.
(2007), and examined under a light microscope. All cells and
tissues were visualized with a Zeiss microscope (Germany)
and images were taken using an AxioCam MRm (Zeiss,
Germany). Image processing and fluorescence quantification
were performed with ImageJ software (NIH, USA).Statistical analysis
The results are expressed as means ± standard error of
the mean (SEM). “n” represents the number of individual
experiments. Statistical analysis was performed using the
two-tailed Student's t-test. Asterisks and crosses in the figure
panels refer to statistical probabilities. Statistical probability
values of less than 0.05 were considered significant.
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PB transposition efficiency in primarymesoangioblasts
PB-mediated gene transfer was shown to be functional in
a range of cell lines (Ding et al., 2005; Chen et al., 2010;
Nakazawa et al., 2009). However, PB transposon vectors
have not been assessed in the context of primary muscle
progenitor cells. To do so, we designed a series of transposon
donor plasmids containing the Puro and the GFP reporter
genes under the control of the SV40 promoter and strong
CMV-GAPDH enhancer–promoter fusion, respectively, brack-
eted by the transposon ITRs (Fig. 1). To prevent potential
chromatin-mediated silencing effects, the hMAR 1–68 or a
control neutral spacer DNA sequence was inserted between
the Puro and GFP genes, so as to investigate the effect of
the MAR element on transposition efficiency and transgene
expression independently of transposon size (Girod et al.,
2007). As an excess or deficit of the PB transposase affects
transposition efficiency (Grabundzija et al., 2010), we first
evaluated transposition in response to varying ratios of the
transposon donor plasmid and transposase expression vector
following PEI mediated transfection. The transposition effi-
ciency was determined from the number of GFP-expressingFigure 2 Transposition efficiency and expression from different tr
were either transfected using PEI reagent or electroporated, with e
negative control vector (open boxes), and with the Puro-GFP, Pu
indicated. Cells were cultured without antibiotic selection for thre
cells was determined by flow cytometry (A). Alternatively, the cells
was quantified from the polyclonal populations of GFP-expressing
**P b 0.01; ***P b 0.001).mesoangioblasts obtained with or without the expression of
the PB transposase after three weeks of culture without
selection following the transfection, to determine the optimal
plasmid ratio, which was used in following assays (Fig. S1).
When using the Puro-GFP transposon and expressing the
transposase, approximately 1% of the unselected cells
maintained expression following PEI-mediated transfection
(Fig. 2A). In contrast, gene transfer by electroporation
yielded up to 8% of the mesoangioblasts stably expressing
GFP in the mesoangioblast cell populations. The use of the
larger transposons resulting from the inclusion of the spacer
or hMAR 1–68 control resulted in a decreased proportion of
GFP-expressing cells (51% and 39% respectively compared to
that of the Puro-GFP vector), but still yielded around 3% of
expressing cells upon the electroporation of the transposon
donor and transposase expression plasmids. The number of
mesoangioblasts stably expressing GFP from the Puro-Spacer
and Puro-MAR transposon vectors was respectively 49%
and 59% lower than that of the Puro-GFP vector, which
paralleled well the transient GFP expression observed two
days after gene transfer, implying that it is the DNA transfer
efficacy that limits transposition success (Fig. S2). In the
absence of the transposase, electroporation or PEI-mediated
transfection yielded very low proportions of fluorescentansposon constructs and transfection methods. Mesoangioblasts
ither the transposase expression vector (filled boxes) or with a
ro-Spacer-GFP or Puro-MAR-GFP transposon donor plasmid, as
e weeks after transfection, and the percentage of GFP positive
were sorted by cytofluorometry, and the fluorescence average
cells (B). Values represent the means ± SEM (n = 3; *P b 0.05;
395A PiggyBac-mediated approach for muscle gene transfer or cell therapycells, ranging between 0.1 and 0.2% (Fig. 2A). This indicated
that spontaneous plasmid integration results from quite
infrequent events in these primary cells.
Factors influencing expression from PB transposable
vectors in mesoangioblasts
The GFP expression levels obtained by transposition or
recombination events were quantified by flow cytometry
assays of the stable mesoangioblast polyclonal populations.
The fluorescence intensity of the GFP-expressing cells was
similar for all conditions when the transposon donor plasmid
was co-transfected with the transposase expression vector
(Fig. 2B). Thus, the presence of the MAR or the size of the
transposon did not affect the high expression levels obtained
from the strong CMV enhancer and GAPDH promoter fusion
upon transposition. However, when it was substituted by the
relatively weaker SV40 promoter, the presence of the MAR
increased both the occurrence of GFP-positive cells and their
expression levels (Fig. S3). Upon the spontaneous plasmid
integration observed without the transposase expression
vector, the expression levels were also significantly increased
by the inclusion of the MAR in electroporated plasmids, even
when the strong CMV-GAPDH promoter was used (Figs. 2B
and S4). Thus, we concluded that this MAR is functional in
the context of transposable or plasmid vectors in primaryFigure 3 Transgene copy number and normalized expression in u
GFP transgenes relative to those of the mouse genome FTSJ2 gene
described in Fig. 2B, following the cytofluorometric sorting of GFP-p
was divided by the number of integrated transgenes, so as to estim
Values represent the means ± SEM (n = 3, *P b 0.05; **P b 0.01).mesoangioblasts. The MAR-mediated expression activation
observed upon the use of a weaker promoter or upon
spontaneous plasmid integration into the genome can be
attributed to the known effects of this MAR to activate
plasmid genomic integration by spontaneous recombina-
tion, to increase transgene transcription, and/or to suppress
chromatin-mediated epigenetic silencing events linked to
integration at unfavorable genomic loci (Grandjean et al.,
2011; Galbete et al., 2009; Majocchi et al., 2014).
To distinguish the effects linked to transgene copy number
variations from those elicited by changes in transgene
transcription levels, we next assessed the copy number of
the genome-integrated transposons in GFP-expressing cells.
PB vector transposition led to the integration of 1 to 5
transgene copies on average in unselected mesoangioblasts
(Fig. 3A). The copy number of spontaneously integrated
plasmid copies was low upon PEI-mediated transfection or
upon electroporation of the smaller plasmid, but the copy
number was increased to 10 copies or more when the larger
plasmids were electroporated in the absence of transposase.
However, the expression levels were quite low despite the
high transgene copy number, indicating that many of the
transgenes were not expressed in a functional form (Fig. 3B).
Indeed, the low level of expression per transgene copy may
result from the DNA strand breaks caused by the electropo-
ration of large plasmids, leading to the possible integration ofnselected mesoangioblasts. (A) The copy number of integrated
was determined using qPCR in unselected cells generated as
ositive cells. (B) The mean fluorescence of the cell populations
ate the average expression per integrated GFP transgene copy.
396 D. Ley et al.fragmented or damaged genes (Goldberg and Rubinsky, 2010).
This mechanism also explains well the increased transgene
copy number observed from the electroporation of large
plasmids when compared to PEI transfection, as ruptured DNA
strands promote the recombination of plasmids, which leads
to concatemer formation, and their genomic integration
(Grandjean et al., 2011). Nevertheless, expression of the
transposase almost fully suppressed this effect, indicating that
the transposase-mediated events predominate, as expected
from the fact that spontaneous integration of functional
transgenes is infrequent in these cells (Fig. 2A).
When the cells expressing the transgenes at the highest
levels were selected by the addition of puromycin to the
mesoangioblast cultures, higher transgene copy numbers
were often observed in the absence of the transposase,
when compared to non-selected cells (compare Figs. S4A and
3A). This is expected from the propensity of plasmids to form
large concatemers before genomic integration by recombi-
nation, which usually results in the insertion of multiple
plasmid copies within one integration locus (Folger et al.,
1982; Hoglund et al., 1992). This was accompanied by
increased expression levels from the MAR-containing plas-
mids, but not from the transposed vectors (Figs. S4B and S5).
In contrast, the transgene copy number did not increase
in selected cells relative to non-selected cells upon the
transposition from the smaller Puro-GFP donor plasmid
following electroporation (compare Figs. S4A and 3A). This
indicated a homogeneously low number of integrated trans-
poson copies in the unselected polyclonal cell population,
as desired for a cell therapy use. Interestingly, the MAR did
not increase the transgene copy number obtained from
the spontaneous integration of plasmids in the genome
of mesoangioblasts, in contrast to its effect to increase
transgene copy number in transformed cell lines (Grandjean
et al., 2011; Galbete et al., 2009). This likely reflects the low
propensity of these primary cells to spontaneously recombine
plasmid vectors into their genome, which is also a favorable
property of the mesoangioblasts for therapeutic applications.
When the GFP expression was normalized to the transgene
copy number, the highest expression level was obtained from
the electroporation of the MAR or spacer-devoid Puro-GFP
transposon in the presence of the transposase (Fig. 3B). This
finding is consistent with previous proposals that transpos-
able vectors have a propensity to integrate at genomic loci
that are permissive for expression (Ley et al., 2013; Galvan
et al., 2009; Matasci et al., 2011), where the presence of a
MAR may be not needed. This also indicated that reliable
transgene expression may be obtained by the integration
of just 1–2 Puro-GFP transposon copies in the genome of
mesoangioblasts. This conclusion was further supported by
the assay of the GFP expression persistence from polyclonal
mesoangioblast populations. After 1 month of culture without
antibiotic selection, the percentage of GFP expressing
cells and the fluorescence intensity remained highest from
mesoangioblasts electroporated with the Puro-GFP transpos-
able vector (Fig. S6). Overall, we therefore concluded that the
use of the strong CMV-GAPDH promoter coupled to a PB
transposon vector can fully alleviate the relatively low levels
of expression that were observed upon spontaneous plasmid
integration, and that reliable expression can be obtained in a
high proportion of the primary cells from the use of this
transposable vector.PB integration site analysis in the mesoangioblasts
We next assessed the overall pattern of PB integration in the
mesoangioblast genome. The transposon–genome junctions
were PCR-amplified using ITR-specific and degenerate primers,
followed by DNA sequencing (Lu et al., 2007). True transposi-
tion was distinguished from spontaneous integration events by
the presence of the transposon ITR and of the characteristic
TTAA sequence footprint marking the border between the
transposon and the genome. This approach allowed the
recovery of 22 distinct transposition events from various
transposable vectors, which were mapped to the mouse
genome (Fig. 4A). Distinct integration events were found in
12 chromosomes, often with multiple occurrences within the
same chromosome, as illustrated by the 6 integrations located
in distinct loci of chromosome 6.
We then examined the tendency of the PB transposon to
integrate in genes or intergenic regions and if the type of
transposable vector may influence the integration prefer-
ence. A random pattern of integration should reflect the
proportion of gene and non-gene DNA sequences present in
the mouse genome, which was estimated to consist of
approximately 70% of intergenic regions (Sakharkar et al.,
2005). Overall, 73% of the retrieved transposon integrations
were found in intergenic regions, and the highest proportion
of intergenic inserts, over 85%, was obtained with the
Puro-GFP transposon (Fig. 4B), implying that this transposon
vector does not have a preference for integration in coding
sequences. Of the 6 integration sites located within gene
coding sequences, 5 occurred in intronic sequences and 1 in
an exon–intron junction. To investigate if the transposons
may integrate preferentially in regulatory regions located
upstream of coding sequences such as promoters or
enhancers, we plotted the occurrence of integration events
relative to gene positions on either side of the integration
sites. This indicated that most transposition events occurred
at distances over 10 kb from the nearest coding sequence
(Fig. 4C). Intergenic integration sites were mainly scattered
beyond 10,000 bp and only one integration site was found
within 1000 bp of an initiation site. However, when the
occurrence of integration events was correlated to the
interval length, the propensity of transposon insertion
appeared to be highest within 10 kb of upstream sequences
(Fig. 4D). This finding may in part explain the high and stable
expression observed from few transposition events, given
the known occurrence of a transcription-permissive chromatin
structure on active and even inactive enhancers (Andersson
et al., 2014). Overall, these findings are consistent with the
lack of preferential transposon integration in coding se-
quences. Moreover, in the observed cases of transposition in
the vicinity of genes, these results suggest a tropism for
permissive chromatin environments such as those of upstream
regulatory regions.
To further assess the number and the type of integration
events, three GFP-positive mesoangioblast clones were
randomly isolated and characterized for the transgene copy
number, GFP expression and integration sites (Table 1). Two
of the clones displayed a single transposon copy integrated
at more than 100 kb of the nearest known gene, and they
showed comparable GFP expression levels. The third clone
revealed two different integration loci, one of which being
within an intron, and it was found to express higher levels of
Figure 4 Sites of PB transposon integration preference in stable unselected GFP-expressing mesoangioblasts. 22 transposon
integration sites were retrieved by chromosomal–transposon junction sequencing and mapped onto the mouse genome. (A) The
number of PB integrations on each of the mouse chromosomes is shown. (B) Proportion of integration in genes or intergenic regions
relative to the different transposon integration sites analyzed in this study. (C) Distribution of the transposon integration loci relative
to the gene coding sequences on either side. The absolute numbers of integration events are given. (D) Frequency of transposition
events relative to gene coding sequences. The number of integration events was normalized to 1000 bp windows, so as to estimate
the propensity of transposons to integrate in coding and regulatory sequences or in intergenic regions irrespective of their relative
size and proportion of the genome.
397A PiggyBac-mediated approach for muscle gene transfer or cell therapyGFP. These results were consistent with those obtained from
the analysis of polyclonal populations, and they demonstrat-
ed that sustained transgene expression could be readily
obtained from a unique transposition event.In vitro and in vivo differentiation
of mesoangioblasts
An important key feature of mesoangioblasts is their ability to
differentiate intomyotubes in vitro, and intomyofibers in vivoTable 1 PB vector integration site environment and expression i
Clone Integration
locus
Copy
number
Integration
features a
C2 Chr9 1 Intergenic
C3 Chr13 1 Intergenic
Chr4 1 Intronic
C7 Chr6 1 Intergenic
a Locations of insertion sites were determined using UCSC genome w
b TSS: transcription start site.
c RLU: relative light unit.upon transplantation into muscles. Stable GFP-expressing
polyclonal mesoangioblast populations obtained by PB trans-
position were first characterized using an in vitro differenti-
ation assay. This consisted of co-culturing themesoangioblasts
with the C2C12 muscle progenitor cells under differentiation
promoting conditions, where C2C12 cells form myotubes
characterized by sarcomeric α-actinin expression (Fig. 5A).
The presence of GFP-positive myotubes expressing sarcomeric
α-actinin after co-culturing was indicative of mesoangioblast
differentiation into myotubes and of the maintenance of GFP
expression.n mesoangioblast cell clones.
Distance from TSS b Relative GFP
fluorescence
At 5′ At 3′ RLU c Per copy
−296,858 117,982 10 10
−70,000 50,000
– – 65 37.5
−410,537 983,902 5 5
eb-browser (mouse, December 2011 assembly).
398 D. Ley et al.We next tested the potential of mesoangioblasts to
differentiate in vivo upon their transplantation in the
Tibialis anterior muscle of immunodeficient nude mice one
day after being electroporated with the Puro-GFP transpo-
son vector. GFP expression was readily detected from whole
muscles following the transplantation of mesoangioblasts
electroporated with the Puro-GFP and PB transposase
plasmids, and expression was maintained after one, two or
six months (Fig. 5B). Muscle cross-sections revealed
the fusion of the mesoangioblasts with the muscle fibers in
vivo and persistent transgene expression, as illustrated
by the strong cytosolic GFP signal displayed by the
myofibers. In contrast, the GFP fluorescence was weaker in
muscles transplanted with mesoangioblasts that were notFigure 5 Mesoangioblast in vitro and in vivo differentiation assay. (A
were co-cultured with C2C12 cells under low-serum differentiation-p
GFP-positive mesoangioblasts appear green. Myotubes immunostaine
arrow on the merged image shows GFP mesoangioblast fusion
(B) Mesoangioblasts electroporated with the Puro-GFP transposon p
plasmids were injected 24 h after in the Tibialis muscle of nude m
cross-section (scale bars = 50 μm) muscle is shown 10, 30, 60
Alexa594-conjugated agglutinin (red) to visualize the myofiber m
cross-section were quantified 10, 30, 60 and 180 days after injection. V
significant differences between +PB and no PB groups; P b 0.05).electroporated with the transposase expression vector,
where the fluorescence was confined to few muscle areas
and was not stably maintained at the later time points. The
proportion of GFP-positive myofibers was higher in muscles
transplanted with mesoangioblasts transfected with the
transposase expression plasmid at each time point, ranging
from 10 to 50% of the myofibers in representative fluorescent
areas, whereas cells transfected without the transposase
yielded 1.5 to 25% of positive myofibers (Figs. S7 and S8). As
the distribution of fluorescent myofibers was not homoge-
neous, we estimated the percentage of the fluorescent area
over entire cross-sections along the muscles, to provide a
more reliable and quantitative representation of the efficien-
cy of the gene transfer approaches (Fig. 5C). Over 20% of the) Stable GFP-expressingmesoangioblasts obtained by transposition
romoting conditions for five days. Nuclei were stained with DAPI.
d for the presence of sarcomeric α-actinin appear in red. White
with C2C12 cells appearing in yellow. Scale bars = 50 μm.
lasmid and the PB transposase (+PB) or empty control (no PB)
ice. GFP fluorescence of the whole (scale bars = 200 μm) and
and 180 days after injection. Sections were stained with
embranes. (C) GFP fluorescence areas of the entire muscle
alues represent themeans ± SEM (n = 2–3; *Indicates statistically
399A PiggyBac-mediated approach for muscle gene transfer or cell therapymuscle area showed GFP fluorescence following the trans-
plantation of cells transfected with the PB transposase vector
after 6 months, corresponding to a 35-fold increase when
compared to the muscles transplanted with mesoangioblasts
devoid of the transposase, which was close to the background
fluorescence of muscles injected with non-transfected
mesoangioblasts. This suggested that transposition had oc-
curred and that it led to the more sustained transgene
expression.
Transposition of the Puro-GFP transposon vector in vivo
was confirmed at the molecular level by the recovery of
muscles and the determination of 10 genomic transposon
integration sites by PCR amplification and DNA sequencing of
the junctions of the vector ITR and cellular chromosomes
(Table S1). 1 transposon had integrated in an exon, whereas
4 transposon integration events occurred in introns, reveal-
ing a possible increase of the frequency of integration within
genes after transplantation when compared to the frequen-
cy found in transposed mesoangioblast in vitro (50% vs. 27%).
Although these numbers do not allow definitive conclusions
on the relative frequencies of genic integration, they
nevertheless indicated that such events do occur from the
transposable vectors, and they are reminiscent of several
prior studies that reported different viral vector integration
patterns before and after transduced cell transplantation
(Ronen et al., 2011; Mantovani et al., 2009; Wang et al.,
2009). Nevertheless, analysis of muscles dissected 2 months
after the transplantation did not reveal any detectable
cytotoxic effects, as observed from the quasi-absence of
regenerating myofibers with central nuclei (Fig. S8), and
they did not show any noticeable sign of inflammation,
necrosis or tumor formation in any of the transplanted
muscles.
The direct transfer of the transposon donor and
transposase expression plasmids in the Tibialis muscles of
healthy mice by intramuscular DNA injection and in vivo
electroporation, termed electrotransfer, was also assessed for
comparison with the mesoangioblast transplantation-based
approach. One week after the electrotransfer, the explanted
micemuscles expressed comparable GFP levels in about 20% of
muscle fibers (Fig. 6). Muscles containing the GFP transposon
donor plasmid but without the PB transposase displayed
substantial levels of GFP over 250 days after the
electrotransfer, and the proportion of GFP positive fibers
was quite similar to that observed after 7 days. The
maintenance of fluorescence at this time point is expected
from the known persistence of episomal plasmids in the
quiescent myofibers (Molnar et al., 2004; Stockdale and
Holtzer, 1961), whereas expression of MAR-devoid plasmids
usually decreases gradually thereafter (Puttini et al., 2013).
However, in the presence of the transposase, the GFP
fluorescence intensity unexpectedly decreased from the
mouse muscles at a much faster pace, starting from 1 month
post-electrotransfer to reach non-detectable levels at
9 months.
Potential toxic effects elicited by the electrotransfer of
the PB transposase expression-vector were assessed from
the occurrence of centrally nucleated muscle fibers, as a
marker of regeneration resulting from myofiber damage.
Centrally nucleated muscle fibers and cellular infiltrates
were observed in muscles 1 month post-electrotransfer
when compared to untreated controls (Fig. S9), which mayresult from muscle damages resulting from the electropora-
tion process, as documented previously (Hartikka et al.,
2001). However, inclusion of the transposase vector did not
increase significantly the number of centrally nucleated
muscle fibers or of cellular infiltrates when compared to
muscles containing the transposase sequence-devoid control
plasmid.
Persistence of the PB transposase plasmid in the
myofibers was explored by qPCR analysis (Fig. S10A). The
PB transposase plasmid was detected 7 days after electro-
poration and it decreased close to the background signal
obtained without DNA electrotransfer after 1 month. Similar
observations were obtained from the electrotransfer of
the muscles of dystrophin-devoid mdx mice that may be
more prone to muscle fiber degeneration. Finally, the PB
transposase activity in myofibers was assessed by means of
its transposon excision and integration properties. After
excision of the transposon, the linear donor plasmid can be
religated by cellular DNA repair activities, yielding a shorter
product upon PCR amplification (Mitra et al., 2008). Excised
products were detected in mice electroporated with the PB
transposase plasmid, revealing that the PB transposase was
active in myofibers in vivo (Fig. S10B). This was confirmed
by the DNA sequencing of 4 transposon–genome junction
events, providing direct evidence of PB transposition
(Table S1). Overall, these findings indicated that the PB
transposase was functional in myofibers, that its expression
was not associated to detectable toxic effects, and that it
mediated transposon vector integration into the multinucleat-
ed muscle fibers' genome from direct plasmid electrotransfer,
despite the observed gradual loss of expression.
Taken together, these results indicated that the PB
vector was capable of mediating persistent transgene
expression in undifferentiated mesoangioblasts in vitro as
well as in differentiated muscle fibers upon their transplan-
tation in vivo. They also showed that stable and wide areas
of expression can be obtained from the transplantation of
mesoangioblasts electroporated with transposon vectors in
vitro, as opposed to the direct in vivo electroporation of the
transposon vector. Finally, mesoangioblast transplantation
was not accompanied by the signs of myofiber damage and
inflammation elicited by plasmid electrotransfer, which
should be of advantage when considering the transplantation
of diseased muscles as in the Duchenne muscular dystrophy.Discussion
Several prior studies reported on the successful isolation of
mesoangioblasts, their in vitro culture, and the maintenance
of their potential to differentiate into myotubes (Farini
et al., 2009). The transplantation ofwild-typemesoangioblasts
was shown to improve significantly muscle function in canine
models of Duchene muscular dystrophy (Sampaolesi et al.,
2006; Galvez et al., 2006). However, the transplantation of
allogeneic healthy mesoangioblasts requires a continued
immunosuppressive therapy, whereas the expression of
dystrophin in autologous dystrophic mesoangioblasts using
viral vectors displayed modest therapeutic benefits. Thus,
the development of gene therapies for myopathies by
autologous cell transplantation remains challenged by
current gene transfer approaches, which have either a low
Figure 6 GFP fluorescence from direct PB transposon electrotransfer in Tibialis mouse muscles. The MAR containing or MAR devoid
transposon donor plasmid was introduced with or without the PB transposase expression vector, as indicated, in murine Tibialis
anterior muscles by direct electrotransfer of the plasmid DNA. GFP fluorescence in cross section of mouse muscles (A), and the mean
percentage of GFP fluorescence of cross-sectional area (B), were determined at different time points following the electrotransfer,
as for Fig. 5 (n = 4). Scale bars = 500 μm.
400 D. Ley et al.efficacy for large coding sequences or result in the expression
of truncated dystrophin derivatives. Here, we assessed the
potential benefit of using PB transposon vectors for sustained
transgene expression in cultured mesoangioblasts and
upon their differentiation into muscle fibers following
transplantation.
We show that the PB transposon and its transposase are
functional and quite efficient in terms of stable gene
transfer to primary mesoangioblasts when compared to the
transfection of plasmid vectors. Transposition occurred even
when using large transposons comprising two expression
cassettes and a spacer or MAR element. The decrease of
transposition efficiency observed with the larger transpo-
sons was paralleled by the lower transient transfection
efficiency of the larger plasmids. This may therefore result
from the known lower efficiency of the transfer of larger
plasmids, which was previously shown to be inversely
proportional to the size of the transfected DNA (Kreiss
et al., 1999). This negative effect of large cargo DNA wasreduced when using electroporation, a method that confers
high transient expression but that may result in a lower
frequency of integration of functional transgene copies.
Here we show that the electroporation of the larger plasmids
may lead to reduced expression despite the integration of
many and probably often non-functional transgene copies in
the absence of the transposase. However, expression of the
transposase and vector transposition yielded low and
homogenous copy numbers of well-expressed transgenes,
and thus it nearly abolished these unwanted effects while
allowing expression in 3–8% of the total cell population in
the absence of any selection. Thus, transposition remained
efficient in primary mesoangioblasts even when using
transposons over 11 kb, in agreement with studies per-
formed on other types of undifferentiated primary cells
(Ding et al., 2005).
This study also shows that transposition can lead to higher
expression levels per integrated transgene copy when com-
pared to spontaneous plasmid integration, and that this high
401A PiggyBac-mediated approach for muscle gene transfer or cell therapyand persistent expression is mediated by few transposition
events. Inclusion of a MAR element to reduce silencing effects
was not accompanied by higher or more sustained expression
in mesoangioblasts when placed next to potent promoter and
enhancer sequences within the transposon vector, which
contrasts with its requirement to achieve maximal transgene
expression in cultured cell lines (Ley et al., 2013). This might
reflect the less prominent silencing effects of undifferentiated
primary cells, or a different tropism of the PB transposase in
terms of the chromatin structure of the targeted genomic DNA
in these cells.
The PB transposase was proposed to preferentially
integrate single copies of the transposon at genomic loci
with a chromatin structure that is permissive for expression,
whereas spontaneous plasmid integration occurs from rare
recombination events of multiple copies of concatemerized
plasmids with the cell genome, increasing the probability of
transgene silencing (Folger et al., 1982; McBurney et al.,
2002). The integration of a high number of plasmid copies
was especially prominent following the antibiotic selection
of cells having integrated plasmids in their genome by
spontaneous recombination, as surviving clones expressing
the antibiotic resistance gene often possessed a high plasmid
copy number. This was not observed with the PB transposon
vector, where the number of transgene copies remained
within 1–3 copies, even following antibiotic selection,
indicating a homogeneously low number of integrated
transposon in the unselected polyclonal cell population.
The propensity of some gene therapy viral vectors to
integrate near the promoter or within the transcribed
portion of cellular genes has been well documented
(Gabriel et al., 2012; Nowrouzi et al., 2012). Whether the
PB transposon may integrate preferentially at or near
transcription units has also been the subject of several
studies, and a preferential integration within or near
transcribed genes has also been observed in some of the
studies, although it may be influenced by the cell type and/
or from biases introduced by the selection of cells expressing
high levels of an antibiotic resistance gene (Wilson et al.,
2007; Galvan et al., 2009; Huang et al., 2010). Here we
found that the transposition of PB vectors may not occur
preferentially in the genes of unselected mesoangioblast
populations, since 73% of the recovered integration events
were found in intergenic regions, mainly beyond 10 kb from
the nearest transcribed gene sequence, although genic
integration events were also observed. Furthermore, we
demonstrated the feasibility of obtaining mesoangioblast
clonal populations expressing GFP at stable levels from a
single intergenic transposon integration site. These stable
mesoangioblast clones maintained their ability to differen-
tiate in vivo and to mediate GFP expression. These findings
support the rationale of using PB transposon vectors to
develop stem cell based therapeutic approaches.
Finally, we provide molecular evidence for PB transposase
activity in vivo after plasmid intramuscular injection and
electrotransfer of the murine muscles, for instance from the
recovery and sequencing of several transposon–genomic
junctions. Interestingly, such integration events were not
able to mediate sustained transgene expression, as the GFP
fluorescence declined for themuscles electroporatedwith the
PB transposase expression vector. In contrast, GFP expression
was more stable when the electrotransfer was performed inthe absence of the transposase, which has been associated
with the spontaneous genomic integration of episomal plasmid
vectors in prior studies (Puttini et al., 2013). The cause of the
lack of persistent expression from in vivo electroporated
transposable vectors in the presence of the transposase
remains unclear at present. It may include the persistence of
low levels of the episomal transposase vector, leading to the
remobilization of the transposons until they would either
integrate into repressive chromatin structure or be lost from
abortive transposition events. Alternatively, toxicity resulting
from the persistent expression of the transposase episomal
expression plasmid cannot be fully excluded, even if no signs
of myofiber necrosis or regeneration were observed.
The loss of expression was nevertheless not observed from
the transplantation of mesoangioblasts first electroporated
with the transposon donor plasmid and transposase expression
vector in vitro, followed by their transplantation in vivo.
Thus, transposition in dividing mesoangioblasts allowed
sustained expression in vivo, even after their transplanta-
tion and differentiation to fuse with resident myofibers.
Overall, this study thus provides a first proof-of-principle of
the feasibility of gene transfer mediated by transposon
vectors in mesoangioblasts in vitro and in myofibers in vivo.
The PB transposon vectors may offer several advantages for
gene transfer over other non-viral or plasmid-based methods,
such as a higher frequency of cells stably expressing the cargo
gene without the need of antibiotic selection, and/or a lower
propensity to epigenetic silencing effects. Relative to viral
vectors, the PB transposon allows the efficient integration
of larger transgenes in undifferentiated and myofiber-
differentiated mesoangioblasts, providing a rationale for the
assay of PB transposon vectors to achieve stable dystrophin
transfer in animal models of Duchenne muscular dystrophy.
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